Carnosine And Anti-Ageing
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
CoQ10 is a molecule found in your cells’ power stations (mitochondria) that helps convert food into energy your brain can use. It also protects brain cells from damage caused by the energy-making process itself. Your body produces less CoQ10 as you age, and deficiency appears in people with brain conditions like Alzheimer’s and Parkinson’s disease.
Research shows CoQ10 works well in animal studies and shows promise for mood disorders based on human trials. However, the main unsolved problem is whether standard oral supplements actually reach the brain in meaningful quantities, because the brain has a protective barrier that limits what gets through. This explains why clinical trials for treating Parkinson’s and Alzheimer’s have underperformed compared to animal research.
CoQ10 is safe and has strong benefits elsewhere in the body, particularly for people taking statin drugs. For brain health specifically, a daily dose of 100 to 200mg with food is a reasonable, low-risk choice based on the biology involved, though don’t expect dramatic short-term changes. Better delivery methods are being researched and may improve results in the coming years.
Verdict: CoQ10’s role in brain energy is biologically sound and worth considering as a long-term protective measure, but current evidence doesn’t support claims it can prevent or reverse Alzheimer’s or Parkinson’s disease through standard supplementation.
What if the reason you’re feeling mentally sluggish in your 40s and 50s isn’t simply stress, poor sleep or too much on your plate, but something happening at a far more fundamental level? Inside every one of your brain cells, billions of tiny power stations are working around the clock. And there’s one molecule that keeps those power stations running. Without it, the lights start to dim. The question isn’t whether CoQ10 matters for your brain. The question is whether we can do anything useful about it.
Vitacuity has analysed over 1.77 million research papers to bring you the most relevant science on this topic. Here’s what we found, honestly, clearly and without the hype.
Coenzyme Q10, also known as ubiquinone, is a naturally occurring molecule found in almost every cell in the human body, with particularly high concentrations in energy-demanding tissues like the brain and heart [7]. Think of it as a critical relay runner in your cells’ energy relay race.
Inside the mitochondria (your cells’ power stations), there’s a process called the electron transport chain, essentially a biological assembly line that converts the food you eat into ATP, the actual currency your cells run on. CoQ10 is the molecule that carries electrons along this chain, making the whole process work [13]. No CoQ10, no ATP. No ATP, no energy.
But CoQ10 doesn’t stop there. It also exists in what’s called its “reduced form”, ubiquinol, which is one of the most potent antioxidants your body makes. In this form, CoQ10 actively neutralises the damaging free radicals produced during energy generation [13]. Given that the brain is extraordinarily rich in fats and consumes more oxygen than almost any other organ, it is also uniquely vulnerable to this kind of oxidative damage [10]. CoQ10 sits right at the crossroads of energy production and protection.
Here’s the uncomfortable bit: your body’s natural CoQ10 production declines with age. And it’s not a small decline. Researchers have identified lower CoQ10 levels in patients with Parkinson’s disease, Alzheimer’s disease, and a range of other neurological conditions [3]. Whether the deficiency causes these conditions or is a result of them is one of the central questions researchers are still wrestling with, but the association is compelling enough to take seriously.
Evidence grade: Strong for the mechanism; Promising for supplementation effects in humans
The mechanistic case for CoQ10 in brain health is about as well-established as it gets in nutritional neuroscience. Research published in *Metabolic Brain Disease* (2025) examined CoQ10’s neuroprotective role in aging rats, specifically looking at its effects on oxidative stress, neuroinflammation, a process researchers now call “inflammaging”, and a cellular clean-up process called autophagy [1]. The findings pointed to CoQ10 actively suppressing the kind of chronic, low-grade inflammation that accumulates in aging brain tissue and is associated with cognitive decline.
What makes this mechanistically interesting is the autophagy angle. Autophagy is essentially your cells’ recycling system, it clears out damaged proteins and dysfunctional mitochondria. When this process breaks down in aging brains, cellular debris accumulates. CoQ10 appears to support the continuation of this process [1], acting like a maintenance crew keeping the power station clean as well as running.
It’s important to be honest here: this was an animal study on rats. We cannot automatically apply the results to humans. But the mechanism it describes is consistent with what we understand about human brain aging, and it adds biological plausibility to the broader body of evidence.
Evidence grade: Promising (preclinical); Conflicted (clinical)
A 2025 review in a peer-reviewed journal explored CoQ10’s potential role in Alzheimer’s disease, specifically its ability to reduce a type of inflammation driven by a protein called interleukin-17 (IL-17) [2]. You don’t need to know what IL-17 is. What matters is this: it’s a signalling molecule that, when overactive, can damage the blood-brain barrier (the protective filter around your brain) and activate inflammatory immune cells inside the brain itself.
CoQ10, according to preclinical data reviewed in this paper, appears to dampen IL-17’s damaging effects, reduce the formation of amyloid-beta plaques (the protein clumps associated with Alzheimer’s), and help restore mitochondrial stability in brain cells [2]. In animal and lab-based studies, it also appeared to improve cognitive function.
The same review is candid about the limitations: clinical trials in humans have produced mixed results. This conflict is real and worth understanding. The leading explanation, which we’ll return to, is that CoQ10 may struggle to cross the blood-brain barrier in sufficient quantities when taken as a standard oral supplement [3].
This is not a reason to dismiss the research. It’s a reason to understand what we’re actually trying to do when we supplement, and to keep an eye on how the science of delivery systems develops.
Evidence grade: Conflicted
The story of CoQ10 and Parkinson’s disease is one of the most instructive examples of the gap between promise and proof in nutritional neuroscience.
The biological rationale is solid. Parkinson’s disease involves the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra [4]. Mitochondrial dysfunction and oxidative stress are now considered central to this process. CoQ10 is an essential electron carrier in the very mitochondrial machinery that breaks down in Parkinson’s, and research from as early as 2003 showed it offered substantial neuroprotection in animal models [8, 12].
A 2025 mechanistic review went further, identifying three specific protective pathways: CoQ10 supports mitochondrial function, inhibits a damaging process called ferroptosis (a form of cell death driven by iron-dependent oxidative damage), and helps recycle other antioxidants in the brain [4]. It’s a genuinely impressive biological profile.
And yet, clinical trials have been a consistent source of disappointment [3]. RCTs in Parkinson’s patients supplementing with CoQ10 have not produced the dramatic results the animal studies predicted. This is frustrating, but the explanation matters: the most credible hypothesis is that standard oral CoQ10 supplementation doesn’t reliably get enough CoQ10 into the brain to replicate what researchers achieved in controlled animal settings [3]. The blood-brain barrier, the molecular gateway protecting your brain, may be limiting how much supplemental CoQ10 actually reaches its target.
The research doesn’t say CoQ10 doesn’t work in Parkinson’s. It says we don’t yet know how to get it where it needs to go in sufficient quantities.
Evidence grade: Promising
Here’s one that tends to raise eyebrows. A 2026 systematic review and meta-analysis, the gold standard of research design, pooled data from five randomised controlled trials involving 474 participants and looked at whether CoQ10 supplementation could improve depressive symptoms [5].
The finding was meaningful: CoQ10 significantly reduced depressive symptoms compared to placebo, with a standardised mean difference of -0.68 (95% CI: -1.02 to -0.33; p<0.01) [5]. In plain English, that’s a moderate, statistically significant effect. Participants included people with depression linked to multiple sclerosis, breast cancer, polycystic ovary syndrome, as well as primary major depression and bipolar disorder.
The rationale connects directly back to mitochondria. Depression has increasingly been linked to mitochondrial dysfunction and oxidative stress, the same mechanisms CoQ10 addresses at a cellular level [5]. If your brain cells can’t produce sufficient energy, mood regulation suffers. This isn’t a fringe theory; it’s gaining serious traction in psychiatry.
A note of honesty: five trials and 474 participants is enough to take seriously, but not enough to be definitive. The heterogeneity across trials (I² = 58%) tells us the results varied meaningfully between studies. And the evidence for fatigue specifically was inconclusive, based on only two trials [5]. This is a promising finding that deserves larger, longer trials, not a settled answer.
Evidence grade: Promising
A 2012 review published in *Headache* made an interesting argument: that migraine is, at least in part, a disorder of mitochondrial energy metabolism in the brain [6]. This reframes migraine not merely as a headache condition but as a signal that brain cells are struggling to meet their energy demands, and that CoQ10, as a central component of mitochondrial function, might have a role in prevention.
The same review also noted that CoQ10’s role is closely connected to riboflavin (vitamin B2), which feeds into the same energy-producing pathways. Both have been investigated as prophylactic (preventive) therapies for migraine [6]. A broader 2021 review of CoQ10’s clinical applications confirmed this, listing migraine alongside neurodegenerative and neuromuscular conditions as areas of active research interest [15].
This is more confirmatory of the mechanistic role of CoQ10 in brain energy than a definitive treatment claim, but it adds another piece to the picture of why a brain-energy molecule might matter well beyond the conditions we typically associate with mitochondrial disease.
Evidence grade: Early stage (on solutions); Strong (on the problem itself)
Let’s talk honestly about the biggest open question in CoQ10 research for brain health. A 2025 overview published specifically on CoQ10 and the blood-brain barrier laid this out clearly [3, 14]: while CoQ10 deficiency is consistently observed in neurological disorders, and while supplementing CoQ10 produces robust results in animal studies, RCTs in humans with Parkinson’s disease, Alzheimer’s disease and ALS have produced disappointing outcomes.
The leading explanation? We don’t yet know with certainty whether oral CoQ10 supplementation can reliably cross the blood-brain barrier in humans in meaningful quantities [3]. Blood levels of CoQ10 do rise with supplementation, that much is clear. But whether that translates into increased brain CoQ10 is a different question entirely, and one that human research hasn’t fully answered.
This doesn’t mean supplementation is pointless. CoQ10 has well-established benefits elsewhere in the body, including cardiovascular protection. And its antioxidant and mitochondrial roles in tissues that don’t face the same barrier challenges are well-supported [13]. But for specifically targeting brain neurodegeneration, the honest picture is that we need better delivery mechanisms and better human trials before we can make confident claims about reversing or preventing conditions like Alzheimer’s or Parkinson’s.
The research is not saying CoQ10 doesn’t reach the brain. It’s saying we’re not certain enough yet, and that this uncertainty probably explains why some clinical trials have underperformed relative to expectations.
Let’s be direct about the gaps, because they matter.
The blood-brain barrier question remains unresolved. It’s the central issue in CoQ10 brain research. We know CoQ10 deficiency appears in diseased brains. We know animal studies show remarkable protection. We don’t yet know with certainty whether standard oral supplementation meaningfully raises CoQ10 levels inside the human brain [3, 14].
Clinical trial results are genuinely mixed. RCTs in Parkinson’s disease, Alzheimer’s disease and ALS have not replicated the results seen in preclinical research [3]. This is likely a delivery problem rather than a “CoQ10 doesn’t work” problem, but that distinction is important and not yet fully resolved.
The optimal dose and form are unclear. CoQ10 comes in different forms, ubiquinone (the oxidised form) and ubiquinol (the active, reduced form). There is ongoing debate about which is more bioavailable and effective, particularly in older adults whose ability to convert ubiquinone to ubiquinol may be reduced [13]. Research into newer, more bioavailable formulations is ongoing but early-stage.
The mood findings need replication. The meta-analysis on depression showed a meaningful signal across five RCTs, but 474 participants across heterogeneous populations is not yet a definitive answer [5]. We need larger, longer trials with consistent methodologies.
Most of the neuroprotection data is still in animals. The 2025 studies on CoQ10’s effects on aging, neuroinflammation and autophagy are conducted in rats [1, 9]. The mechanisms are biologically plausible in humans, but plausible isn’t proven.
Here’s how a sensible, well-informed person should think about CoQ10 for brain health in 2025.
The mechanistic case is genuinely compelling. CoQ10 is not a fringe supplement or a wellness trend, it is a molecule your mitochondria depend on, your body makes less of as you age, and which is consistently found to be deficient in people with neurological conditions [7, 13]. That is not a small thing.
The honest limitation is that the evidence for dramatic disease reversal in conditions like Alzheimer’s or Parkinson’s through standard oral supplementation is not there yet, primarily because of the blood-brain barrier problem [3]. Don’t let anyone sell you CoQ10 as a cure or prevention for these conditions. The science doesn’t support that yet.
But here’s the practical reality: CoQ10 is fat-soluble and accumulates to some degree in tissues, not rapidly excreted like water-soluble vitamins. At standard doses (typically 100–300mg daily), it has an excellent safety profile and is well-tolerated in human trials [13]. The cardiovascular benefits are separately well-established [13]. And for your mitochondria generally, not just in your brain, maintaining adequate CoQ10 levels as you age makes biological sense.
What would a sensible, informed person actually do?
– If you’re over 40 and taking a statin (statins are known to deplete CoQ10), supplementation is a clear practical priority, this is one of the most compelling and widely-accepted use cases for CoQ10. – For general brain energy support, a daily dose of 100–200mg with a meal containing healthy fats (CoQ10 is fat-soluble and absorbs better this way) is a reasonable, low-risk intervention given the mechanistic rationale and the body of supporting evidence. – Look for ubiquinol formulations if you’re over 50, the body’s ability to convert standard ubiquinone to its active form may decline with age [13]. – Don’t expect a dramatic short-term cognitive transformation. CoQ10’s value for brain health is likely a slow, protective, background effect, the kind of thing that matters over years and decades, not weeks. – Watch this space. The science of CoQ10 delivery, particularly getting it reliably across the blood-brain barrier, is an active and genuinely exciting area. Better formulations may change the picture for neurodegeneration meaningfully in the coming years [3].
The bottom line? CoQ10 is one of those supplements where the biology is hard to argue with, the safety is not in question, and the remaining uncertainty is largely about delivery and mechanism rather than whether the molecule itself matters. For a 40-65-year-old serious about long-term brain health, that’s a reasonable basis for including it in your daily routine.
[1] Coenzyme Q (2025). DOI: 10.1007/s11011-025-01721-8 | https://pubmed.ncbi.nlm.nih.gov/41182484/
[2] The Potential of Coenzyme Q10 in Alzheimer’s Disease: Reducing IL-17 Induced Inflammation and Oxidative Stress for Neuroprotection (2025). https://pubmed.ncbi.nlm.nih.gov/40277120/
[3] Coenzyme Q10 and the Blood-Brain Barrier: An Overview (2025). https://pubmed.ncbi.nlm.nih.gov/40283578/
[4] Mechanistic insights into ubiquinone Q10 in Parkinson’s disease: mitochondrial protection, ferroptosis inhibition, and antioxidant recycling (2025). DOI: 10.1080/13813455.2025.2541698 | https://pubmed.ncbi.nlm.nih.gov/40762836/
[5] Effects of Coenzyme Q10 Supplementation on Depressive Symptoms and Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026). DOI: 10.1097/JCP.0000000000002112 | https://pubmed.ncbi.nlm.nih.gov/41294251/
[6] CoEnzyme Q10 and riboflavin: the mitochondrial connection (2012). https://pubmed.ncbi.nlm.nih.gov/23030537/
[7] Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases (2023). https://pubmed.ncbi.nlm.nih.gov/37946741/
[8] Targeting cellular energy production in neurological disorders (2003). DOI: 10.1517/13543784.12.10.1655 | https://pubmed.ncbi.nlm.nih.gov/14519086/
[9] Coenzyme Q (2025). DOI: 10.1007/s11011-025-01721-8 | https://pubmed.ncbi.nlm.nih.gov/41182484/
[10] Therapeutic Effects of Coenzyme Q10 in the Treatment of Ischemic Stroke (2024). https://pubmed.ncbi.nlm.nih.gov/39227555/
[11] The Potential of Coenzyme Q10 in Alzheimer’s Disease: Reducing IL-17 Induced Inflammation and Oxidative Stress for Neuroprotection (2025). https://pubmed.ncbi.nlm.nih.gov/40277120/
[12] Bioenergetic approaches for neuroprotection in Parkinson’s disease (2003). DOI: 10.1002/ana.10479 | https://pubmed.ncbi.nlm.nih.gov/12666097/
[13] Preclinical and Clinical Role of Coenzyme Q10 Supplementation in Various Pathological States (2022). DOI: 10.1055/a-1835-1738 | https://pubmed.ncbi.nlm.nih.gov/35724675/
[14] Coenzyme Q10 and the Blood-Brain Barrier: An Overview (2025). https://pubmed.ncbi.nlm.nih.gov/40283578/
[15] Coenzyme Q (2021). DOI: 10.3390/nu13051697 | https://pubmed.ncbi.nlm.nih.gov/34067632/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156424/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Quick Read Homocysteine is a natural byproduct of protein metabolism that can accumulate in your blood and damage blood vessels,
